TET2 and CREBBP mutations are mutually exclusive in DLBCL, suggesting that they control the same pathways.39 Loss of TET2 renders DLBCL cells dependent on HDAC3, suggesting a potential therapeutic approach for TET2‐mutant DLBCL patients.39 Here, HDAC3 is linked to diffuse large B-cell lymphoma.